Inovio Pharmaceuticals (NASDAQ:INO) released its earnings results on Thursday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.02), Bloomberg Earnings reports. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 128.73%. During the same quarter in the previous year, the firm earned ($0.07) earnings per share.
INO traded down $0.05 during midday trading on Friday, reaching $2.49. The company had a trading volume of 731,552 shares, compared to its average volume of 646,966. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $249.01 million, a PE ratio of -2.37 and a beta of 2.03. Inovio Pharmaceuticals has a 12-month low of $2.15 and a 12-month high of $6.30. The business’s 50-day moving average price is $2.81.
In other Inovio Pharmaceuticals news, insider Laurent Humeau purchased 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $50,000.00. Following the purchase, the insider now owns 45,833 shares of the company’s stock, valued at approximately $114,582.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jong Joseph Kim sold 136,768 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $3.50, for a total transaction of $478,688.00. Following the sale, the chief executive officer now owns 2,511,055 shares in the company, valued at $8,788,692.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,882,673 shares of company stock worth $7,099,911. Corporate insiders own 7.90% of the company’s stock.
A number of research analysts have weighed in on INO shares. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Tuesday, June 11th. Piper Jaffray Companies dropped their target price on shares of Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 17th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $3.50 target price on the stock. in a research note on Tuesday, May 28th. Finally, BidaskClub cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.69.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: Stock Split
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.